A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways

Science Signaling

Volumn 7, Issue 325, 2014, Pages

  Morton, Stephen W ^a,b   Lee, Michael J ^a   Deng, Zhou J ^a   Dreaden, Erik C ^a   Siouve, Elise ^a   Shopsowitz, Kevin E ^a   Shah, Nisarg J ^a   Yaffe, Michael B ^a,c   Hammond, Paula T ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CISPLATIN; DOXORUBICIN; DRUG CARRIER; ERLOTINIB; FOLIC ACID; GEFITINIB; LAPATINIB; LIPOSOME; MACROGOL; NANOPARTICLE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; FEMALE; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; ANIMAL; BAGG ALBINO MOUSE; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG CARRIERS; FEMALE; LIPOSOMES; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; QUINAZOLINES;

EID: 84900563057     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005261     Document Type: Article

References (29)

1. R. A. Weinberg, The Biology of Cancer (Garland Science, Taylor & Francis Group LLC, New York, 2007), p. 864.
2. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
3. M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger, G. MacBeath, M. B. Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
4. J. B. Fitzgerald, B. Schoeberl, U. B. Nielsen, P. K. Sorger, Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006).
5. D. X. Kong, X. J. Li, H. Y. Zhang, Where is the hope for drug discovery? Let history tell the future. Drug Discov. Today 14, 115-119 (2009).
6. L. Xie, T. Evangelidis, P. E. Bourne, Drug discovery using chemical systems biology: Weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLOS Comput. Biol. 7, e1002037 (2011).
7. W. Dai, W. Jin, J. Zhang, X. Wang, J. Wang, X. Zhang, Y. Wan, Q. Zhang, Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes. Pharm. Res. 29, 2902-2911 (2012).
8. S. Sengupta, D. Eavarone, I. Capila, G. Zhao, N. Watson, T. Kiziltepe, R. Sasisekharan, Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568-572 (2005).
9. F. Szoka Jr., D. Papahadjopoulos, Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu. Rev. Biophys. Bioeng. 9, 467-508 (1980).
10. E. Buck, A. Eyzaguirre, J. D. Haley, N. W. Gibson, P. Cagnoni, K. K. Iwata, Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol. Cancer Ther. 5, 2051-2059 (2006).
11. L. Smith, M. B. Watson, S. L. O'Kane, P. J. Drew, M. J. Lind, L. Cawkwell, The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther. 5, 2115-2120 (2006).
12. D. Drummond, O. Meyer, K. Hong, D. Kirpotin, D. Papahadjopoulos, Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51, 691-743 (1999).
13. A. Gabizon, A. T. Horowitz, D. Goren, D. Tzemach, H. Shmeeda, S. Zalipsky, In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 9, 6551-6559 (2003).
14. A. Gabizon, D. Tzemach, J. Gorin, L. Mak, Y. Amitay, H. Shmeeda, S. Zalipsky, Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother. Pharmacol. 66, 43-52 (2010).
15. R. Lee, P. Low, Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269, 3198-3204 (1994).
16. Y. Lu, P. Low, Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54, 675-693 (2002).
17. V. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145-160 (2005).
18. W. Xia, P. S. Low, Folate-targeted therapies for cancer. J. Med. Chem. 53, 6811-6824 (2010).
19. F. Perche, V. Torchilin, Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J. Drug Deliv. 2013, 705265 (2013).
20. S. Aryal, C. M. J. Hu, L. Zhang, Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol. Pharm. 8, 1401-1407 (2011).
21. R. H. Fang, S. Aryal, C. M. J. Hu, L. Zhang, Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir 26, 16958-16962 (2010).
22. C. M. J. Hu, S. Aryal, L. Zhang, Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 1, 323-334 (2010).
23. A. Singh, F. Dilnawaz, S. Mewar, U. Sharma, N. R. Jagannathan, S. K. Sahoo, Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy. ACS Appl. Mater. Interfaces 3, 842-856 (2011).
24. H. L. Wong, R. Bendayan, A. M. Rauth, X. Y. Wu, Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release 116, 275-284 (2006).
25. A. Baeza, E. Guisasola, E. Ruiz-Hernández, M. Vallet-Regí, Magnetically triggered multidrug release by hybridmesoporous silica nanoparticles. Chem. Mater. 24, 517-524 (2012).
26. N. R. Patel, A. Rathi, D. Mongayt, V. P. Torchilin, Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int. J. Pharm. 416, 296-299 (2011).
27. R. C. Smith, M. Riollano, A. Leung, P. T. Hammond, Layer-by-layer platform technology for small-molecule delivery. Angew. Chem. Int. Ed. Engl. 48, 8974-8977 (2009).
28. K. A. Janes, H. C. Reinhardt, M. B. Yaffe, Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell 135, 343-354 (2008).
29. M. Yokoyama, T. Okano, Y. Sakurai, S. Suwa, K. Kataoka, Introduction of cisplatin into polymeric micelle. J. Control. Release 39, 351-356 (1996).